Prot# KIN-1902-2002: A Randomized, Double-blind, Placebo-controlled, Phase 2a Study with an Open-label Cohort to Assess the Safety, Tolerability, and Efficacy of Namilumab in Subjects with Active Cardiac Sarcoidosis

Project: Research project

Project Details

StatusActive
Effective start/end date6/29/226/29/25

Funding

  • Covance Inc. (Prot# KIN-1902-2002)
  • Kinevant Sciences GmbH (Prot# KIN-1902-2002)